Results 161 to 170 of about 115,987 (377)

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger   +6 more
wiley   +1 more source

Efecto inhibitorio de un extracto acuoso de las hojas de Allophylus cominia (L.) Sw sobre las proteínas tirosina fosfatasa 1B y dipeptidil peptidasa IV [PDF]

open access: yes, 2014
Introduction: Allophylus cominia (L.) Sw is a Cuban medicinal plant used by traditional medicine for the treatment of diabetes with unknown mechanisms of action.
L. Harvey, Alan   +3 more
core  

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen   +12 more
wiley   +1 more source

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

open access: yesBiochemical Pharmacology, 2021
R. Yazbeck, S. Jaenisch, C. Abbott
semanticscholar   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear.
Changyuan Yang   +6 more
wiley   +1 more source

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2010
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes.
Kushner P
doaj   +2 more sources

Hempseed Water-Soluble Protein Fraction and Its Hydrolysate Display Different Biological Features

open access: yesLife
Hempseeds, from the Cannabis sativa plant, and its derivates are a versatile food option for various dietary preferences. Due to their aminoacidic profile, researchers have studied the presence of bioactive peptides in hempseed proteins.
Annalisa Givonetti   +7 more
doaj   +1 more source

The Risk of Immune-Mediated Skin Disease Under Dipeptidyl-Peptidase IV Inhibitor: A Global Population-Based Study. [PDF]

open access: yesInt J Dermatol
International Journal of Dermatology, Volume 65, Issue 2, Page 356-358, February 2026.
Mruwat N   +3 more
europepmc   +2 more sources

Dipeptidyl Peptidase-4 Inhibitor

open access: yesKorean Journal of Medicine, 2014
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are two known incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), of which the former is a more important therapeutic target for type 2 diabetes.
openaire   +1 more source

Home - About - Disclaimer - Privacy